| Autor: |
Luis García de Guadiana-Romualdo, Mónica Martínez Martínez, María Dolores Rodríguez Mulero, Patricia Esteban-Torrella, Marta Hernández Olivo, María José Alcaraz García, Valerio Campos-Rodríguez, Natalia Sancho-Rodríguez, María Galindo Martínez, Antonia Alcaraz, María Salomé Ros Braquehais, Carlos Báguena Perez-Crespo, Verónica Ramos Arenas, Cristina Tomás Jiménez, Luciano Consuegra-Sánchez, Andrés Conesa-Hernandez, Pascual Piñera-Salmerón, Enrique Bernal-Morell |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
International Journal of Infectious Diseases, Vol 111, Iss , Pp 211-218 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
1201-9712 |
| DOI: |
10.1016/j.ijid.2021.08.058 |
| Popis: |
Objectives: Thromboinflammation, resulting from a complex interaction between thrombocytopathy, coagulopathy, and endotheliopathy, contributes to increased mortality in COVID-19 patients. MR-proADM, as a surrogate of adrenomedullin system disruption, leading to endothelial damage, has been reported as a promising biomarker for short-term prognosis. We evaluated the role of MR-proADM in the mid-term mortality in COVID-19 patients. Methods: A prospective, observational study enrolling COVID-19 patients from August to October 2020. A blood sample for laboratory test analysis was drawn on arrival in the emergency department. The primary endpoint was 90-day mortality. The area under the curve (AUC) and Cox regression analyses were used to assess discriminatory ability and association with the endpoint. Results: A total of 359 patients were enrolled, and the 90-day mortality rate was 8.9%. ROC AUC for MR-proADM predicting 90-day mortality was 0.832. An optimal cutoff of 0.80 nmol/L showed a sensitivity of 96.9% and a specificity of 58.4%, with a negative predictive value of 99.5%. Circulating MR-proADM levels (inverse transformed), after adjusting by a propensity score including eleven potential confounders, were an independent predictor of 90-day mortality (HR: 0.162 [95% CI: 0.043-0.480]) Conclusions: Our data confirm that MR-proADM has a role in the mid-term prognosis of COVID-19 patients and might assist physicians with risk stratification. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
